MetaADEDB 2.0 @ LMMD
amprenavir
(YMARZQAQMVYCKC-OEMFJLHTSA-N)
Structure
SMILES
CC(CN(S(=O)(=O)c1ccc(cc1)N)C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)O)C
Type(s)
Approved; Investigational
ATC code(s)
J05AE05
Molecular Formula:
C25H35N3O6S
Molecular Weight:
505.627
Log P:
4.4557
Hydrogen Bond Acceptor:
9
Hydrogen Bond Donor:
3
TPSA:
139.57
CAS Number(s):
161814-49-9
Synonym(s)
1.
amprenavir
2.
141W94
3.
Agenerase
4.
VX 478
5.
VX-478
6.
Vertex VX478
7.
tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate
External Link(s)
MeSHC095108
PubChem Compound65016
BindingDB50215393
577
ChEBI40050
CHEMBLCHEMBL116
DrugBankDB00701
DrugCentral200
KEGGcpd:C08086
dr:D00894
Therapeutic Target DatabaseD0A0OO
ZINC3809192
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Blood cholesterol increasedFAERS: 1US FAERS
2Blood triglycerides increasedFAERS: 1OFFSIDES
SIDER
US FAERS
3Pharmaceutical product complaintFAERS: 1US FAERS
4Abdominal PainSIDER
5Abdominal discomfortOFFSIDES
SIDER
6Abdominal symptomSIDER
7AcanthosisOFFSIDES
8AcidosisOFFSIDES
9Acquired Protein S DeficiencyOFFSIDES
10Acute Coronary SyndromeSIDER
11Acute myocardial infarctionOFFSIDES
12AdenitisOFFSIDES
13Alanine Aminotransferase IncreasedSIDER
14Amylase increasedSIDER
15AngioedemaSIDER
16Anogenital dysplasiaOFFSIDES
17AnorexiaSIDER
18AnxietyOFFSIDES
19ApathyOFFSIDES
20Arteriogram coronary abnormalOFFSIDES
21ArthropathyOFFSIDES
22Aspartate Aminotransferase IncreasedSIDER
23Aspiration PneumoniaOFFSIDES
24AstheniaSIDER
25Atrial tachycardiaOFFSIDES
26Bacteria stool identifiedOFFSIDES
27Bipolar I disorderOFFSIDES
28BlepharoptosisOFFSIDES
29Blood GlucoseOFFSIDES
30Blood HIV RNAOFFSIDES
31Blood alkaline phosphatase increasedOFFSIDES
32Blood amylase increasedOFFSIDES
33Blood cholesterolOFFSIDES
34Blood creatine phosphokinase increasedOFFSIDES
SIDER
35Blood parathyroid hormone increasedOFFSIDES
36Brain natriuretic peptide increasedOFFSIDES
37BronchiectasisOFFSIDES
38Buffalo humpSIDER
39CD4 lymphocytes increasedOFFSIDES
40Cardiac TamponadeOFFSIDES
41Chest PainOFFSIDES
42Circumstance or information capable of leading to medication errorOFFSIDES
43Coagulation factor VII level increasedOFFSIDES
44Coagulation factor VIII level increasedOFFSIDES
45Creatine Phosphokinase IncreasedSIDER
46CystOFFSIDES
47DemyelinationOFFSIDES
48Depressive disorderSIDER
49DermatitisSIDER
50DiabetesOFFSIDES
51Diabetes MellitusSIDER
52DiarrheaOFFSIDES
53DiscomfortSIDER
54Disease recurrenceOFFSIDES
55Drug administration errorOFFSIDES
56Drug ineffectiveOFFSIDES
57Drug resistanceOFFSIDES
58Drug withdrawal headacheOFFSIDES
59Dry skinOFFSIDES
60Dyspeptic signs and symptomsSIDER
61Dysthymic DisorderSIDER
62EpistaxisOFFSIDES
63Erythema MultiformeSIDER
64Eye painOFFSIDES
65Facial wastingOFFSIDES
66Fat redistributionOFFSIDES
SIDER
67FatigueOFFSIDES
SIDER
68Fatty LiverOFFSIDES
69FlatulenceSIDER
70Gamma-Glutamyltransferase IncreasedOFFSIDES
71Gastrointestinal PainSIDER
72HIV Infections11365545
16639341
20660842
CTD
73HIV Wasting SyndromeOFFSIDES
74HeadacheSIDER
75Hepatitis BSIDER
76Hydronephrosis18771058CTD
77HypercapniaOFFSIDES
78Hypertrophy of BreastSIDER
79HypoxiaOFFSIDES
80ImmunosuppressionOFFSIDES
81ImpetigoOFFSIDES
82IncontinenceOFFSIDES
83InflammationSIDER
84Injection site burningOFFSIDES
85Injection site erythemaOFFSIDES
86Injection site irritationOFFSIDES
87Injection site massOFFSIDES
88Injection site pruritusOFFSIDES
89Insulin ResistanceSIDER
90Intraocular inflammationOFFSIDES
91Kidney Calculi18771058CTD
92LeukoencephalopathyOFFSIDES
93Leukopenia neonatalOFFSIDES
94Lip erosionOFFSIDES
95LipaseOFFSIDES
96Lipodystrophy acquiredOFFSIDES
SIDER
97LipodystrophySIDER
98LipohypertrophyOFFSIDES
SIDER
99LymphomaOFFSIDES
100MacrocytosisOFFSIDES
101Malabsorption from injection siteOFFSIDES
102MalnutritionSIDER
103MastoiditisOFFSIDES
104Mental status changesOFFSIDES
105Metastases to adrenalsOFFSIDES
106MononeuritisOFFSIDES
107Multiple allergiesOFFSIDES
108Muscle WeaknessOFFSIDES
109Muscle necrosisOFFSIDES
110Musculoskeletal discomfortSIDER
111MyalgiaSIDER
112Myocardial Infarction20660842CTD
SIDER
113MyositisSIDER
114NasopharyngitisOFFSIDES
115NauseaOFFSIDES
SIDER
116NephrolithiasisSIDER
117NeutropeniaSIDER
118No adverse effectOFFSIDES
119NoduleOFFSIDES
120NystagmusOFFSIDES
121ObstructionOFFSIDES
122OphthalmoplegiaOFFSIDES
123OverweightOFFSIDES
124Performance status decreasedOFFSIDES
125Perioral paraesthesiaSIDER
126PolyuriaOFFSIDES
127Portal Vein ThrombosisOFFSIDES
128Protein total decreasedOFFSIDES
129PruritusSIDER
130Pseudomonal sepsisOFFSIDES
131QuadriparesisOFFSIDES
132Renal tubular disorderOFFSIDES
133Renal tubular necrosisOFFSIDES
134RhabdomyolysisSIDER
135RhinitisOFFSIDES
136SclerodermaOFFSIDES
137Sense of oppressionOFFSIDES
138Sick Sinus SyndromeOFFSIDES
139SinusitisOFFSIDES
140Stevens-Johnson Syndrome25811541CTD
SIDER
141Taste DisordersSIDER
142Transaminases increasedSIDER
143TremorSIDER
144Viral load decreasedOFFSIDES
145Viral mutation identifiedOFFSIDES
146Visual tracking test abnormalOFFSIDES
147VomitingSIDER
148Von Willebrand's factor multimers abnormalOFFSIDES
149nervous system disorderSIDER
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.